NIH Clinical Center: Search the Studies

Search the Studies

27 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.

Please note that only the first 5 legal search words are being processed.

Protocol Number	Title	Protocol Status	Min-Max Age	Institute	Keywords
000862-CH	Pilot Study of the Use of Functional Near-Infrared Spectroscopy (fNIRS) Combined with Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical Controls	Participants currently recruited/enrolled	0-110 Years	NICHD	Diffuse
000860-C	A Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations	Participants currently recruited/enrolled	18-125 Years	NCI	Diffuse
000633-C	Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies	Participants currently recruited/enrolled	18-125 Years	NCI	Diffuse
000516-C	Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous System	No longer recruiting/follow-up only	18-125 Years	NCI	Diffuse
000326-H	A Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies	Participants currently recruited/enrolled	18-125 Years	NHLBI	Diffuse
000274-C	Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas	Clinical hold/Recruitment or enrollment suspended	18-125 Years	NCI	Diffuse
000193-C	Phase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell Lymphomas	Completed Study; data analyses ongoing	18-125 Years	NCI	Diffuse
22-C-0003	Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis	Participants currently recruited/enrolled	18-39 Years	NCI	Diffuse
21-C-0014	Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma	Participants currently recruited/enrolled	18-120 Years	NCI	Diffuse
20-C-0069	A First-In-Human Phase I Single-Agent Dose-Escalation and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms	Participants currently recruited/enrolled	18-125 Years	NCI	Diffuse
19-C-0116	A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma	Participants currently recruited/enrolled	18-125 Years	NCI	Diffuse
19-C-0103	A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)	No longer recruiting/follow-up only	18-125 Years	NCI	Diffuse
19-C-0016	Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors	Participants currently recruited/enrolled	0-125 Years	NCI	Diffuse
18-C-0080	Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled Trial	Completed Study; data analyses ongoing	5-125 Years	NCI	Diffuse
17-C-0137	Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing	Enrolling by Invitation	3-65 Years	NCI	Diffuse
17-C-0127	Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma	Participants currently recruited/enrolled	18-125 Years	NCI	Diffuse
17-C-0048	Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas	Completed Study; data analyses ongoing	18-73 Years	NCI	Diffuse
17-C-0043	Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer	Participants currently recruited/enrolled	2-125 Years	NCI	Diffuse
16-I-0078	Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME study)	Participants currently recruited/enrolled	18-49 Years	NIAID	Diffuse
16-C-0097	Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma	Completed Study; data analyses ongoing	2-21 Years	NCI	Diffuse
15-C-0078	Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs	No longer recruiting/follow-up only	18-65 Years	NCI	Diffuse
14-C-0157	Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma	Participants currently recruited/enrolled	18-125 Years	NCI	Diffuse
10-C-0011	Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas	Completed Study; data analyses ongoing	18-125 Years	NCI	Diffuse
06-C-0219	An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System Tumors	Completed Study; data analyses ongoing	0-21 Years	NCI	Diffuse
05-C-0252	Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell Lymphomas	Completed Study; data analyses ongoing	18-125 Years	NCI	Diffuse
01-C-0030	Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas	Completed Study; data analyses ongoing	18-125 Years	NCI	Diffuse
93-C-0133	Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's Lymphoma	Completed Study; data analyses ongoing	12-125 Years	NCI	Diffuse